Share on LinkedInShare on LinkedIn

ARTICLE · 19 JUNE 2026

Evolving And Modernizing Pharmaceutical IP Portfolio Planning

The pharmaceutical industry is approaching one of the most consequential inflection points in its modern history. By 2027, patent expirations on a wave of blockbuster drugs will expose approximately $150 billion in annual revenue to generic and biosimilar competition — a reckoning that is already reshaping how companies build, defend, and monetize their intellectual property.

United StatesIntellectual Property

The pharmaceutical industry is approaching one of the most consequential inflection points in its modern history. By 2027, patent expirations on a wave of blockbuster drugs will expose approximately $150 billion in annual revenue to generic and biosimilar competition — a reckoning that is already reshaping how companies build, defend, and monetize their intellectual property.

A Cliff, Not a Slope

Unlike previous cycles of patent expiration, this wave is notable for its concentration: a cluster of high-revenue medicines — including leading immunology, oncology, and cardiovascular therapies — face loss of exclusivity within a narrow window. For companies that have relied on a few flagship products to anchor their revenue base, the exposure is not gradual. It is abrupt.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from